Download this issueMetabolic agents in the contemporary treatment of angina
EDITORIAL
- Metabolic agents and angina treatment
F. J. Pinto, Portugal
THEMED ARTICLES
- Chronic ischemic heart disease: an energy imbalance
G. Guarini, M. Marzilli, Italy - Mitochondria as a therapeutic target in ischemia
D. J. Hausenloy, United Kingdom - The place of metabolic agents in contemporary coronary artery disease guidelines
L. H. W. Gowdak, Brazil - Revascularization in angina patients: addressing cardiac metabolism challenges
G. D. Lopaschuk, Canada - The endothelium: a therapeutic target in post-PCI patients and the role of trimetazidine in endothelial function
S. Lim, South Korea - Metabolic agents in the protection of patients who undergo revascularization
Y. Chen, China - How effective can trimetazidine be in preventing myocardial and renal revascularization injury?
Y. Lopatin, Russia
CONTROVERSIAL QUESTION
- Is targeting only stenosis sufficient to optimally improve angina?
P. S. Farsky, Brazil – L. O. Go, Philippines – H. Hasan-Ali, Egypt – H. Q. T. Ho, Vietnam – D. Isaza-Restrepo, Colombia – T. Kovarnik, Czech Republic – O. H. Masoli, Argentina – A. N. Parkhomenko and O. S. Gurjeva, Ukraine – C. K. Ponde, India – V. Sansoy, Turkey – D. Vassilev, Bulgaria
VASTAREL MR
- Trimetazidine: targeting the cardiac cell in stable angina
M. Gliebova, France
INTERVIEW
- The ATPCI trial: a new international phase 3 study assessing the clinical impact of adding a metabolic agent to post-PCI angina treatment
R. Ferrari, Italy
FOCUS
- Combining hemodynamic and metabolic agents in ischemic heart disease
G. Fragasso, Italy
UPDATE
- History and evolution of coronary stenting
M. E. Bertrand, France
